ELAVL1 and colorectal carcinoma: Logically, the therapeutic strategies to inhibit HuR, especially in CRC, would be to: 1) silence expression levels [53], 2) disrupt the ARE-binding activity which is mediated through the conserved RNA recognition motifs (RRM) domains of HuR, and 3) inhibit HuR nuclear to cytoplasmic translocation.